ArticleThe Journal of cell biology2020
Analysis of copy number alterations reveals the lncRNA ALAL-1 as a regulator of lung cancer immune evasion.
Article in The Journal of cell biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 70 citations in OpenAlex.
- Long non-coding RNAs in colorectal cancer: shaping the tumour microenvironment and advancing precision oncology.Nature reviews. Gastroenterology & hepatology · 2026Review
- Comparative Copy Number Variation Profiling of GL01, an Immortalized Non-small Cell Lung Cancer Cell Line Derived from a Filipino Patient, and A549 Lung Adenocarcinoma Cells.Acta medica Philippina · 2025Article
- M6A RNA modification: focusing on non-small cell lung cancer progression, therapeutic strategies and challenges.Frontiers in oncology · 2025Review
- Review
- Analysis of lncRNA-related studies of ivermectin-sensitive and -resistant strains of Haemonchus contortus.Parasitology research · 2024Article
- Identification of key immune cells infiltrated in lung adenocarcinoma microenvironment and their related long noncoding RNA.iScience · 2024Article
- Population-level annotation of lncRNAs in Arabidopsis reveals extensive expression variation associated with transposable element-like silencing.The Plant cell · 2023Article
- Comprehensive landscape and future perspective of long noncoding RNAs in non-small cell lung cancer: it takes a village.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Review
- Multi-Omics Mining of lncRNAs with Biological and Clinical Relevance in Cancer.International journal of molecular sciences · 2023Review
- Construction of lncRNA TYMSOS/hsa-miR-101-3p/CEP55 and TYMSOS/hsa-miR-195-5p/CHEK1 Axis in Non-small Cell Lung Cancer.Biochemical genetics · 2023Article
- A novel method to identify and characterize personalized functional driver lncRNAs in cancer samples.Computational and structural biotechnology journal · 2023Article
- Four-copy number alteration (CNA)-related lncRNA prognostic signature for liver cancer.Scientific reports · 2022Article
- An L-theanine derivative targets against SARS-CoV-2 and its Delta and Omicron variants.Heliyon · 2022Article
- The significance of the crosstalk between ubiquitination or deubiquitination and ncRNAs in non-small cell lung cancer.Frontiers in oncology · 2022Review
- Comprehensive Analysis of the Prognostic Signature of Mutation-Derived Genome Instability-Related lncRNAs for Patients With Endometrial Cancer.Frontiers in cell and developmental biology · 2022Article
- Machine Learning-Based Integration Develops a Pyroptosis-Related lncRNA Model to Enhance the Predicted Value of Low-Grade Glioma Patients.Journal of oncology · 2022Article
- New Sights Into Long Non-Coding RNA LINC01133 in Cancer.Frontiers in oncology · 2022Review
- An Immune-Related lncRNA Pairing Model for Predicting the Prognosis and Immune-Infiltrating Cell Condition in Human Ovarian Cancer.BioMed research international · 2022Article
- RNA m6A demethylase FTO-mediated epigenetic up-regulation of LINC00022 promotes tumorigenesis in esophageal squamous cell carcinoma.Journal of experimental & clinical cancer research : CR · 2021Article
- Web tools to perform long non-coding RNAs analysis in oncology research.Database : the journal of biological databases and curation · 2021Review
Corrections and comments
- Commented on by
Authors and funding
17 authors at 3 institutions in 2 countries.
Funding
Abstract
Cancer is characterized by genomic instability leading to deletion or amplification of oncogenes or tumor suppressors. However, most of the altered regions are devoid of known cancer drivers. Here, we identify lncRNAs frequently lost or amplified in cancer. Among them, we found amplified lncRNA associated with lung cancer-1 (ALAL-1) as frequently amplified in lung adenocarcinomas. ALAL-1 is also overexpressed in additional tumor types, such as lung squamous carcinoma. The RNA product of ALAL-1 is able to promote the proliferation and tumorigenicity of lung cancer cells. ALAL-1 is a TNFα- and NF-κB-induced cytoplasmic lncRNA that specifically interacts with SART3, regulating the subcellular localization of the protein deubiquitinase USP4 and, in turn, its function in the cell. Interestingly, ALAL-1 expression inversely correlates with the immune infiltration of lung squamous tumors, while tumors with ALAL-1 amplification show lower infiltration of several types of immune cells. We have thus unveiled a pro-oncogenic lncRNA that mediates cancer immune evasion, pointing to a new target for immune potentiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.